Gene profiling in active dermatitis lesions strengthens the diagnosis of allergic contact dermatitis - Supplemental Material
Description
Supplemental Material: Gene profiling in active dermatitis lesions strengthens the diagnosis of allergic contact dermatitis Marine-Alexia LEFEVRE MD/PhD1-2, Audrey NOSBAUM MD/PhD1-3, Amandine MOSNIER MSc1, Vanina LENIEF MSc1, Samuel SALQUE MSc1, Marie PICHOT MSc1, Lea MAHEUX MSc1, Lea BERTOLOTTI MD3, Florence HACARD MD3, Celine GRAVERIAU MD4, Pascale ZUKERVAR MD4, Anne-Laure BRETON GUITARIAN MD4, Fanny BOISLEVE PharmD/PhD5, Michelle ELBAZ PharmD5, Jean-François NICOLAS MD/PhD1-3, Marc VOCANSON PhD1 Affiliations: 1 CIRI, Centre International de Recherche en Infectiologie, (Team Epidermal Immunity and Allergy); INSERM, U1111; Univ Lyon; Université de Lyon 1; Ecole Normale Supérieure de Lyon; CNRS, UMR 5308, Lyon, France. 2 Department of Dermatology and Allergy, Centre Hospitalier Universitaire de St Etienne, Saint-Priest-en-Jarez, France. 3 Department of Allergy and Clinical Immunology, Centre Hospitalier Lyon-Sud, Pierre-Benite, France. 4 Private Dermatology Practice, Lyon, France 5 Chanel, Neuilly-sur-Seine, France. Background: Distinguishing between allergic and non-allergic forms of Contact Dermatitis (CD) is challenging and requires investigations based on patch-testing. Early detection of allergy biomarkers in active CD lesions could refine and simplify the management of CD patients. Objective: To characterize the molecular signatures of active CD lesions. Methods: We studied the expression of 12 allergy biomarkers by qRT-PCR in active lesions of 38 CD patients. Allergic CD (ACD) was diagnosed based on patch-test (PT) results and exposure assessment. Molecular signatures of active lesions, as well as positive PT reactions, were compared with those of reference chemical allergens and irritants. Results: 19 of the 38 CD patients reacted positively upon patch-testing and exposure assessment confirmed ACD diagnosis for 17 of them. Gene profiling of active CD lesions revealed two distinct molecular patterns: patients harboring signatures similar to reference allergens (n=23) or irritants (n=15). Among the 23 patients with an “allergy signature”, we found the 17 patients with confirmed ACD, while no culprit allergen was identified for the 6 other patients. Interestingly, the 15 patients without biomarker induction had negative PT, suggesting that they developed non-allergic CD reactions. Conclusion: Molecular signatures from active skin lesions may help to stratify CD patients and predict those suffering from allergic contact dermatitis.